Rare CNVs provide novel insights into the molecular basis of GH and IGF-1 insensitivity.
Journal
European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
05
2020
accepted:
17
09
2020
entrez:
15
10
2020
pubmed:
16
10
2020
medline:
28
10
2020
Statut:
ppublish
Résumé
Copy number variation (CNV) has been associated with idiopathic short stature, small for gestational age and Silver-Russell syndrome (SRS). It has not been extensively investigated in growth hormone insensitivity (GHI; short stature, IGF-1 deficiency and normal/high GH) or previously in IGF-1 insensitivity (short stature, high/normal GH and IGF-1). Array comparative genomic hybridisation was performed with ~60 000 probe oligonucleotide array in GHI (n = 53) and IGF-1 insensitivity (n = 10) subjects. Published literature, mouse models, DECIPHER CNV tracks, growth associated GWAS loci and pathway enrichment analyses were used to identify key biological pathways/novel candidate growth genes within the CNV regions. Both cohorts were enriched for class 3-5 CNVs (7/53 (13%) GHI and 3/10 (30%) IGF-1 insensitivity patients). Interestingly, 6/10 (60%) CNV subjects had diagnostic/associated clinical features of SRS. 5/10 subjects (50%) had CNVs previously reported in suspected SRS: 1q21 (n = 2), 12q14 (n = 1) deletions and Xp22 (n = 1), Xq26 (n = 1) duplications. A novel 15q11 deletion, previously associated with growth failure but not SRS/GHI was identified. Bioinformatic analysis identified 45 novel candidate growth genes, 15 being associated with growth in GWAS. The WNT canonical pathway was enriched in the GHI cohort and CLOCK was identified as an upstream regulator in the IGF-1 insensitivity cohorts. Our cohort was enriched for low frequency CNVs. Our study emphasises the importance of CNV testing in GHI and IGF-1 insensitivity patients, particularly GHI subjects with SRS features. Functional experimental evidence is now required to validate the novel candidate growth genes, interactions and biological pathways identified.
Identifiants
pubmed: 33055295
doi: 10.1530/EJE-20-0474
pii: EJE-20-0474
pmc: PMC7592635
doi:
pii:
Substances chimiques
IGF1 protein, human
0
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
581-595Subventions
Organisme : Department of Health
ID : NIHR300098
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R21 HD098417
Pays : United States
Références
Am J Med Genet A. 2016 Apr;170A(4):896-907
pubmed: 26822682
J Med Genet. 2015 Jul;52(7):446-53
pubmed: 25951829
J Clin Endocrinol Metab. 2013 Aug;98(8):E1428-37
pubmed: 23771920
Am J Hum Genet. 2011 Dec 9;89(6):751-9
pubmed: 22118881
Endocr Rev. 2019 Apr 1;40(2):476-505
pubmed: 30265312
Annu Rev Genomics Hum Genet. 2009;10:451-81
pubmed: 19715442
Nat Rev Endocrinol. 2017 Feb;13(2):105-124
pubmed: 27585961
J Med Genet. 2009 Mar;46(3):192-7
pubmed: 19066168
Eur J Hum Genet. 2014 May;22(5):602-9
pubmed: 24065112
Eur J Med Genet. 2011 Mar-Apr;54(2):121-9
pubmed: 21056703
Hum Pathol. 2017 Dec;70:35-42
pubmed: 28601661
J Biol Chem. 2018 Nov 2;293(44):17278-17290
pubmed: 30217816
J Med Genet. 1999 Nov;36(11):837-42
pubmed: 10544228
Am J Med Genet A. 2011 Apr;155A(4):725-31
pubmed: 21594994
Am J Med Genet A. 2005 Sep 15;138(1):11-7
pubmed: 16097007
EMBO Mol Med. 2016 Mar 31;8(4):363-74
pubmed: 26902202
N Engl J Med. 2003 Dec 4;349(23):2211-22
pubmed: 14657428
Hormones (Athens). 2014 Oct-Dec;13(4):552-60
pubmed: 25402377
PLoS Genet. 2013;9(3):e1003365
pubmed: 23516380
N Engl J Med. 2008 Oct 16;359(16):1685-99
pubmed: 18784092
Horm Res Paediatr. 2018;89(1):13-21
pubmed: 29130988
Genet Med. 2018 Feb;20(2):250-258
pubmed: 28796236
Cancer Res. 2007 Dec 1;67(23):11393-401
pubmed: 18056467
Mol Cytogenet. 2016 Feb 16;9:16
pubmed: 26884814
Eur J Hum Genet. 2011 May;19(5):534-9
pubmed: 21267005
Horm Res Paediatr. 2014;82(5):310-8
pubmed: 25300501
Eur J Endocrinol. 2015 Feb;172(2):151-61
pubmed: 25411237
J Med Genet. 2010 Dec;47(12):816-22
pubmed: 19752157
BMC Med Genet. 2017 Oct 23;18(1):118
pubmed: 29061174
Genet Med. 2013 Jun;15(6):478-81
pubmed: 23258348
N Engl J Med. 2003 Sep 18;349(12):1139-47
pubmed: 13679528
BMC Cancer. 2008 Jul 15;8:199
pubmed: 18627596
Eur J Hum Genet. 2012 Jul;20(7):748-53
pubmed: 22258528
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Clin Epigenetics. 2017 May 15;9:52
pubmed: 28515796
World J Gastroenterol. 2014 Feb 28;20(8):1986-92
pubmed: 24587674
PLoS One. 2015 Oct 16;10(10):e0140749
pubmed: 26474182
N Engl J Med. 1996 Oct 31;335(18):1363-7
pubmed: 8857020
J Hum Genet. 2015 Jun;60(6):287-93
pubmed: 25809938
J Pediatr. 2012 Nov;161(5):933-42
pubmed: 22683032
Cell Mol Neurobiol. 2016 May;36(4):565-76
pubmed: 26162969
N Engl J Med. 1989 Oct 12;321(15):989-95
pubmed: 2779634
Clin Cancer Res. 2007 Jul 15;13(14):4042-5
pubmed: 17634527
Endocr Rev. 2011 Aug;32(4):472-97
pubmed: 21525302
N Engl J Med. 2004 Feb 5;350(6):570-7
pubmed: 14762184
Eur J Endocrinol. 2017 Dec;177(6):485-501
pubmed: 28870985
Am J Med Genet A. 2014 Aug;164A(8):1916-22
pubmed: 24715682
Nature. 2013 Dec 19;504(7480):456-9
pubmed: 24226769
Eur J Med Genet. 2009 Mar-Jun;52(2-3):101-7
pubmed: 19298872